Sanofi has acquired Zentiva Slovakia
The public shareholders of Zentiva Slovakia have sold approximately a 3% stake in the company to Sanofi, in a share buyback transaction. Financial details have not been disclosed.
Sanofi is a global and diversified healthcare leader which researches, develops and distributes therapeutic solutions focused on patients’ needs. The company has core strengths in healthcare, with six growth platforms: emerging markets, vaccines, consumer healthcare, diabetes treatments, innovative products and animal health.
Zentiva Slovakia is a producer of pharmaceutical products. Its product range consists of approximately 270 references in 500 pharmaceutical presentations, of which 180 are bound by prescription and 100 are OTC preparations or food supplements. The company focuses on the treatment of cardiovascular disorders, inflammatory conditions, pain, infections and diseases of the central nervous system and the gastrointestinal and urinary tracts. It also offers over-the-counter medicines and dietary supplements. It offers a range of therapeutic areas. In addition to generic drugs, Zentiva Slovakia also produces cosmetics and pharmaceutical substances.
Oaklins' team in Slovakia acted as financial advisor to the buyer in this transaction.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more